Meta AnalysisID 2618
血小板糖蛋白受体拮抗剂治疗缺血性卒中：临床前证据的系统评价
CRD42020182096
Does Platelet Glycoprotein Receptor Antagonist ameliorate ischemic stroke in animal stroke model? Does Platelet Glycoprotein Receptor Antagonist induce severe bleeding events or intracranial hemorrhage? Is Platelet Glyco
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2618
- Evidence Id
- 11176
- Core Evidence Id
- 11176
- Source Meta Analysis Id
- 2570
- Herb2 Meta Analysis Id
- HBMA002570
- Crd Id
- CRD42020182096
- Title
- Platelet Glycoprotein Receptor Antagonist for Ischemic Stroke: A Systematic Review of Preclinical Evidence
- Review Question
- Does Platelet Glycoprotein Receptor Antagonist ameliorate ischemic stroke in animal stroke model? Does Platelet Glycoprotein Receptor Antagonist induce severe bleeding events or intracranial hemorrhage? Is Platelet Glycoprotein Receptor Antagonist superior to aspirin or rt-PA for acute stroke? Context and rationale Stroke may occur for one in six people in their lifetime around the world, and 5.8 million die of it each year. Acute ischemic stroke (AIS) is defined by the sudden loss of blood flow to an area of the brain with the resulting loss of neurologic function. For AIS, demands for more effective and safe thrombolytic agents which can promote revascularization rate and prevent artery re-occlusion are required. GP Receptor Antagonist can block the final common pathway to platelet aggregation by preventing fibrinogen molecules between adjacent platelets from binding. It has been widely used in percutaneous coronary intervention (PCI), but its application on acute stroke is controversial. Randomized control trials investigating GP Antagonist are insufficient and some of them are not well designed. Some clinicians think that GP receptor antagonist may induce severe bleeding events, especially intracranial hemorrhage. Preclinical studies could investigate its efficiency and safety in animal models. If GP recepter antagonist induce intracerebral hemorrhage, its application in human shoud be in doubt. This systematic review of preclinical studies will provide reference for clinical usage of GP Receptor Antagonist.
- Study Type Included
- Inclusion criteria: Controlled studies with one or more than one separate control group. Exclusion criteria: Case studies, cross-over studies, studies without a separate control group.
- Condition Being Studied
- Participant
- Animal
- Inclusion criteria: All animal models with ischemic stroke. Exclusion criteria: All animal models with hemorrhagic stroke.
- Human Disease Modelled
- Ischemic stroke.
- Intervention
- Inclusion criteria: The intervention would be any platelet glycoprotein receptor antagonist(e.g. tirofiban, abciximab) used for ischemic stroke model. All timings, frequencies and dosages of treatment are eligible for inclusion. Exclusion criteria: Number of each group is less than 5.
- Comparator Control
- Inclusion criteria: 1. Vehicle/Placebo-treated control animals. 2. Asprin-treated control animals. 3. Rt-PA-treated control animals. Exclusion criteria: All other control conditions
- Main Outcome
- Outcome Measure
- Inclusion criteria: 1. Cerebral blood flow; 2. Infarct volumes; 3. Neurobehavioral function. 4 Bleeding risk. Exclusion criteria: No relevant outcomes reported.
- Additional Outcome
- Study Method
- Keyword
- Animals; Brain Ischemia; Stroke
- Contact
- Genmao Cao [email protected]
- Organisational Affiliation
- Second hospital of Shanxi medical university
- Funding Source
- No funding. Grant number(s)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Pre-clinical animal intervention review
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-04-27
- Registration Date
- 2020-05-14
- Anticipated Start Date
- 2020-04-30
- Anticipated Completion Date
- 2020-06-30
- Title Cn
- 血小板糖蛋白受体拮抗剂治疗缺血性卒中：临床前证据的系统评价
- Title En
- Platelet Glycoprotein Receptor Antagonist for Ischemic Stroke: A Systematic Review of Preclinical Evidence
- Bilingual Status
- complete